Patients with chronic spontaneous urticaria improved early, with benefits lasting through the 52-week follow-up for those who ...

In September 2024, the FDA approved a new biosimilar for treating retinal conditions, marking a significant development in ...

If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, look no further than the iShares Biotechnology ETF (IBB), a passively managed exchange traded fund ...

Among biopharma firms, size didn’t always correlate with the highest wages, a recently debuted analysis of ‘best’ pharma ...

As part of its extensive offerings for the eczema community throughout October, NEA hosts The Ecz-hibition, a social ...

Regeneron (REGN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan ...